Summary
Metoprolol Succinate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. ClinicalTrials.gov lists 7 registered trials linking Metoprolol Succinate to Hypertension: 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00819104). The largest enrolment is 1900 participants (NCT00642096). Registration activity spans 2003 to 2015. The literature layer holds 5 publications for this pair: 5 clinical trial publications. Publication years run from 2016 to 2026. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 54.0 (trials 24.0, literature 10.0, tier 15, approved bonus 5.0) |
| Registered trials | 7 total: 0 recruiting, 0 active / not yet recruiting, 5 completed, 2 other |
| Linked publications | 5 (5 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00819104 | A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components 2008 | completed | Phase 4 | 402 |
| NCT02612298 | Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate 2015 | completed | Phase 4 | 198 |
| NCT00861016 | Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension 2005 | completed | Phase 4 | 310 |
| NCT01238705 | Combined Antihypertensive Therapy and Sexual Dysfunction 2008 | status unknown | Phase 4 | 280 |
| NCT00642096 | Factorial Study of Metoprolol Succinate TOPROL-XL (324A) 2003 | completed | Phase 3 | 1,900 |
| NCT02336607 | The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. 2005 | completed | Not applicable | 529 |
| NCT00152633 | Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension 2005 | withdrawn | PHASE2, PHASE3 | — |
Published literature
- Clinical trial publication Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover TrialCohen JB, Hossain A, Chittams J et al. · Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42137945
- Clinical trial publication Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled TrialWang M, Chen J, Qi M et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2025 · PMID 40965515
- Clinical trial publication Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical studyWander GS, Ram B, Kumar Sonkar S et al. · Indian heart journal · 2024 · PMID 38871219
- Clinical trial publication Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humansVelasco A, Solow E, Price A et al. · American journal of physiology. Heart and circulatory physiology · 2016 · PMID 27199121
- Clinical trial publication Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood PressureDiehl KJ, Stauffer BL, Dow CA et al. · Hypertension (Dallas, Tex. : 1979) · 2016 · PMID 27113048
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Metoprolol Succinate approved for Hypertension?
Metoprolol Succinate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Metoprolol Succinate in clinical trials for Hypertension?
ClinicalTrials.gov lists 7 registered trials linking Metoprolol Succinate to Hypertension: 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00819104). The largest enrolment is 1900 participants (NCT00642096). Registration activity spans 2003 to 2015.
What does the evidence show for Metoprolol Succinate in Hypertension?
Metoprolol Succinate has 5 completed trials and 5 linked publications for Hypertension. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.